|
Daily Medical Update
Hyperparathyroidism
Thursday, June 25, 2026
|
🔬 Practice-Changing Findings
Evidence from RCTs and meta-analyses published in the
last 12 months.
|
The Journal of Clinical Endocrinology and Metabolism (2025) - Systematic Review
Key Findings
- Less-than-subtotal parathyroidectomy carried higher recurrence than subtotal parathyroidectomy (RR 1.26, 95% CI 1.16-1.36) and total parathyroidectomy with autotransplantation (RR 1.35, 95% CI 1.22-1.49).
- Conservative surgery lowered hypoparathyroidism versus subtotal parathyroidectomy (RR 0.90, 95% CI 0.82-0.98) and total parathyroidectomy with autotransplantation (RR 0.76, 95% CI 0.63-0.90).
- No significant increase in recurrence or hypoparathyroidism risk was seen across preoperative PTH, calcium, or phosphorus strata.
📋 Practice Implication: In MEN1-associated primary hyperparathyroidism, operative planning should explicitly balance lower recurrence from more extensive resection against the higher risk of permanent hypoparathyroidism rather than relying on baseline biochemistry to choose extent.
|
World Journal of Surgical Oncology (2025) - Systematic Review
Key Findings
- Adding transcervical thymectomy reduced persistent hyperparathyroidism from 21.9% to 3.1% (RR 0.15, p < 0.01).
- Recurrent hyperparathyroidism requiring re-operation fell from 43.8% to 12.9% with thymectomy (RR 0.34, p = 0.004).
- Permanent recurrent laryngeal nerve injury was lower with thymectomy (3.9% vs 1.0%; RR 0.32, p = 0.04).
📋 Practice Implication: For MEN1 patients already proceeding to parathyroidectomy, concomitant transcervical thymectomy should be part of the surgical discussion because it appears to improve disease control while not worsening, and possibly improving, morbidity.
|
Head and Neck (2026) - Systematic Review
Key Findings
- Preoperative vitamin D supplementation reduced postoperative hypocalcemia (RR 0.35, 95% CI 0.18-0.66).
- Symptomatic hypocalcemia was also lower with supplementation (RR 0.53, 95% CI 0.29-1.00).
- Length of stay was shorter after supplementation (mean difference -0.51 days, 95% CI -0.55 to -0.46).
📋 Practice Implication: Patients scheduled for parathyroidectomy should have vitamin D deficiency identified and corrected preoperatively when feasible, because this is a modifiable lever for reducing postoperative calcium complications and shortening hospitalization.
|
European Journal of Nuclear Medicine and Molecular Imaging (2026) - Randomized Controlled Trial
Key Findings
- First-line fluorocholine PET/CT achieved higher effectiveness than sestamibi SPECT/CT for imaging-guided minimally invasive parathyroidectomy with normocalcemia at 1 month (85% vs 56%, p = 0.037).
- The mean strategy cost difference was modest at EUR136.5, with average costs of EUR3843.5 for fluorocholine PET/CT versus EUR3707.0 for sestamibi SPECT/CT.
- Cost-effectiveness improved with an incremental cost-effectiveness ratio of EUR471 for one additional patient referred to successful minimally invasive parathyroidectomy followed by normocalcemia.
📋 Practice Implication: Referral pathways for surgical primary hyperparathyroidism can justify earlier fluorocholine PET/CT when available, because improved localization and postoperative normocalcemia appear to come at only a small incremental payer cost.
|
American Journal of Nephrology (2025) - Randomized Controlled Trial
Key Findings
- Extended-release calcifediol increased mean 25-hydroxyvitamin D from 24.1 to 157.7 ng/mL by 12 weeks, while placebo levels fell from 36.0 to 30.6 ng/mL.
- Mean 1,25-dihydroxyvitamin D increased from 9.4 to 50.7 pg/mL, and 93% of treated participants exceeded the lower limit of normal.
- Intact PTH increased 19.8% with placebo but decreased 1.7% with extended-release calcifediol, without observed hypercalcemia, phosphorus rise, or excess adverse events.
📋 Practice Implication: In hemodialysis patients with secondary hyperparathyroidism and low vitamin D status, extended-release calcifediol is a plausible oral option to restore vitamin D physiology and blunt PTH progression before escalating to more burdensome therapies.
|
|
💡
Summary
Recent evidence in hyperparathyroidism is clinically actionable across both operative and nonoperative care. MEN1-focused meta-analyses favor more comprehensive cervical surgery to reduce persistence and recurrence, while perioperative vitamin D repletion, first-line fluorocholine PET/CT localization, and extended-release calcifediol for dialysis-associated secondary hyperparathyroidism each improve management decisions in defined patient groups.
|
|